Table 2.

Intravenous bisphosphonate use and delays

	No delay (n = 24)	Delay (n = 16)	Total (n = 40)
Age (years)	9.8 (3.9–21.3)	10.4 (5.6–34.8)	10.4 (4.3–21.3)
Sex
Male	12 (50%)	8 (50%)	20 (50%)
Female	12 (50%)	8 (50%)	20 (50%)
OI Severity
Mild	14 (58%)	12 (75%)	26 (65%)
Severe	10 (42%)	3 (19%)	13 (33%)
Unknown	0 (0%)	1 (6%)	1 (3%)
Bisphosphonate treatment location
Hospital-based inpatient	2 (8%)	2 (13%)	4 (10%)
Hospital-based outpatient	21 (88%)	13 (82%)	34 (85%)
Home infusion	0 (0%)	1 (6%)	1 (3%)
Multiple	1 (4%)	0 (0%)	1 (3%)
Bisphosphonate infusion interval (months)	4.5 (3–6)	6 (4–9)	6 (3–6)
Delay in receiving bisphosphonates (months)	0 (0–0)	2 (1–3)	2 (1–3)
Reason for bisphosphonate delay
Infusion site not available (1)	0 (0%)	8 (50%)	8 (47%)
Worry about COVID-19 (2)	0 (0%)	4 (25%)	4 (24%)
Reason unrelated to COVID-19 (3)	1 (100%)	1 (6%)	2 (12%)
(1) and (2)	0 (0%)	2 (13%)	2 (12%)
(2) and (3)	0 (0%)	1 (6%)	1 (6%)

Variables are reported as median (interquartile range) or counts (percent)